• Explore /
  • Poster
  • / Pembrolizumab (Pem) in combination with stereotactic body radiotherapy (SBRT) for resectable liver oligometastatic MSS/MMR proficient colorectal cancer (CRC).

Pembrolizumab (Pem) in combination with stereotactic body radiotherapy (SBRT) for resectable liver oligometastatic MSS/MMR proficient colorectal cancer (CRC).

Abstract Video & Slides Poster

Authors

null

Dustin A. Deming

University of Wisconsin Carbone Cancer Center, Madison, WI

Dustin A. Deming , Philip Emmerich , Anita Ahmed Turk , Sam Joseph Lubner , Nataliya Volodymyrivna Uboha , Noelle K. LoConte , Daniel Mulkerin , David H. Kim , Kristina A. Matkowskyj , Sharon M. Weber , Daniel Abbott , Jens C. Eickhoff , Michael Frederick Bassetti

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Colorectal and Anal

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer–Advanced Disease

Clinical Trial Registration Number

NCT02837263

Citation

J Clin Oncol 38: 2020 (suppl; abstr 4046)

DOI

10.1200/JCO.2020.38.15_suppl.4046

Abstract #

4046

Poster Bd #

38

Abstract Disclosures

Similar Posters

First Author: Dustin A. Deming

First Author: Anita Ahmed Turk

First Author: Dustin A. Deming

First Author: Charlee Nardin